Posted by Michael Wonder on 19 Jul 2021
Making sense of the FDA’s ‘indefensible’ decision to approve Aduhelm
19 July 2021 - There are three sides to every story that defies logic: the defenders’ side, the critics’ side and the well hidden truth.
So far, only two sides have been told about the FDA’s accelerated approval of Aduhelm, a controversial drug for patients with Alzheimer’s disease.
